Bazaarvoice Announces Majority Investment from Thomas H. Lee Partners

Bazaarvoice today announced a majority investment from Thomas H. Lee Partners, L.P. (“THL”), a premier private equity firm investing in growth companies.

AUSTIN, Texas, March 26, 2021 (GLOBE NEWSWIRE) — Bazaarvoice, Inc., the leading provider of product reviews and user-generated content (UGC) solutions, today announced a majority investment from Thomas H. Lee Partners, L.P. (“THL”), a premier private equity firm investing in growth companies. Marlin Equity Partners (“Marlin”), the current majority investor in Bazaarvoice, will continue to be a material shareholder.

UGC is one of the most influential factors in driving e-commerce traffic and conversion, and with a network of over 11,500 brands and retailers, Bazaarvoice enables its clients to harness the power of UGC to grow their digital commerce offerings. UGC is pivotal to brand and retailer strategies, especially as more of the consumer shopping journey transitions to digital channels, a shift that has been accelerated by the COVID-19 pandemic. Bazaarvoice provides brands and retailers with technology to collect, moderate, curate, and distribute UGC across more places than ever before in the complex and ever-expanding e-commerce landscape. With Bazaarvoice’s Influenster community, a network of over 6 million consumers writing more than 1 million reviews each month, brands can generate reviews and social content and gain new consumer and product insights.

“Over the last year, Bazaarvoice has grown significantly by expanding its integrated solution portfolio in response to our customers’ increasing and growing need to leverage UGC at scale to drive revenue,” said Keith Nealon, CEO of Bazaarvoice. “Last year, we solidified our position as the only full-funnel platform by acquiring Curalate, a visual and social content offering that helps create product inspiration and allows consumers to make unexpected discoveries. In addition, we launched Network Insights to better help brands understand consumer sentiment trending and relative competitive performance based on feedback from their customers.”

Regarding the transaction announcement, CEO Nealon said “THL shares our and Marlin’s passion for software and content that help companies build and grow their e-commerce businesses. We are excited to partner with THL for the next chapter of growth for Bazaarvoice.”

“Shopping migration from offline to online channels is a trend that we expect to sustain for many years,” said Jeff Swenson, managing director at THL. “Consumers value the voices of other consumers in their shopping journeys, and Bazaarvoice offers marketers a mission-critical set of solutions to help acquire, curate and deliver UGC at scale to their customers. THL is excited to support Bazaarvoice in continuously growing and innovating its software and content offerings to help brands and retailers drive e-commerce revenue.”

“We look forward to joining forces with THL and continuing to accelerate growth at Bazaarvoice,” said Nathan Pingelton, a managing director at Marlin. “We view Bazaarvoice as a world-class business which has become the leading provider of UGC to brands and retailers. Given its compelling value proposition and multiple industry tailwinds, the business is well positioned for continued success.”

UBS and Latham & Watkins acted as exclusive financial and legal advisors to Bazaarvoice. Barclays and Kirkland & Ellis acted as exclusive financial and legal advisors to THL. JPMorgan also acted as financial advisor to Marlin. Terms of the transaction were not disclosed. The transaction is expected to close in calendar Q2 2021.

About Bazaarvoice

Thousands of the world’s leading brands and retailers trust Bazaarvoice technology, services, and expertise to drive revenue, extend reach, gain actionable insights, and create loyal advocates. Bazaarvoice’s extensive global retail, social, and search syndication network, product-passionate community, and enterprise-level technology provide the tools brands and retailers need to create smarter shopper experiences across the entire customer journey.

Founded in 2005, Bazaarvoice is headquartered in Austin, Texas, with offices in North America, Europe, Asia, and Australia. For more information, visit www.bazaarvoice.com.

About THL

Thomas H. Lee Partners, L.P. (“THL”) is a premier private equity firm investing in middle market growth companies exclusively in three sectors: Financial Services, Healthcare and Technology & Business Solutions. THL couples deep sector expertise with dedicated internal operating resources to transform and build great companies of lasting value in partnership with management. The Firm’s domain expertise and resources help to build great companies with an aim to accelerate growth, improve operations and drive long-term sustainable value. Since 1974, THL has raised more than $25 billion of equity capital, invested in over 150 companies and completed more than 400 add-on acquisitions representing an aggregate enterprise value at acquisition of over $200 billion. For more information on THL, please visit www.thl.com.

About Marlin Equity Partners

Marlin Equity Partners is a global investment firm with over $7.8 billion of capital under management. The firm is focused on providing corporate parents, shareholders and other stakeholders with tailored solutions that meet their business and liquidity needs. Marlin invests in businesses across multiple industries where its capital base, industry relationships and extensive network of operational resources significantly strengthen a company’s outlook and enhance value. Since its inception, Marlin, through its group of funds and related companies, has successfully completed over 180 acquisitions. The firm is headquartered in Los Angeles, California with an additional office in London. For more information, please visit www.marlinequity.com.

Media Contacts:

Eleanor Simpson
Bazaarvoice
[email protected]

Lauren Venticinque
Bazaarvoice
[email protected]



Cinemark Rolls Out the Red Carpet with Oscar® Movie Week In-Theatre Festival

Cinemark Rolls Out the Red Carpet with Oscar® Movie Week In-Theatre Festival

Tickets on sale now for movie lovers to catch all of this year’s Best Picture and some of the Best Shorts nominees on the big screen

PLANO, Texas–(BUSINESS WIRE)–Cinemark Holdings, Inc., one of the world’s largest and most influential movie theatre companies, is rolling out the red carpet for the 93rd Oscars® with its annual Oscar® Movie Week festival. From Friday, April 19,through Sunday, April 25, film’s biggest fans can catch all of this year’s Best Picture and some of the Best Shorts nominated films at more than 100 participating Cinemark theatres in partnership with Focus Features. Tickets are now on sale now at Cinemark.com or on the Cinemark app.

“Cinemark is thrilled to be giving the big screen treatment to the past year’s best films and to bring back one of our most popular programs of the year with our annual Oscar® Movie Week,” said Justin McDaniel, Cinemark SVP of global content strategy. “These films and shorts deserve nothing less than the cinematic experience, and there is no place more cinematic than Cinemark with our immersive viewing environment. We are happy to welcome moviegoers back for this time-honored tradition.”

Movie lovers can pick and choose the films they would like to see, whether just a few or Cinemark’s entire Oscar® Movie Week offering. Feature-length Best Picture nominees will be playing in participating Cinemark theatres from April 19 through April 25, and tickets are $5 for each film. Movie enthusiasts looking to just catch the shorts can purchase a $10 ticket to see all shorts between April 23 and April 25. For the full list of nominees included in the festival and to see showtimes and purchase tickets, visit Cinemark.com/movieweek.

Those looking for a big win of their own can follow Cinemark on Instagram and tag a friend on Cinemark’s Oscar® Movie Week Sweepstakes posts from April 6 through April 15 for a chance to win tickets to the festival.

For all details on Oscar® Movie Week, including participating theatres, showtimes and how to purchase tickets, visit Cinemark.com/movieweek.

The Cinemark Standard

The exhibitor has consistently received 96 percent guest satisfaction with Cinemark protecting their health and safety. Moreover, a resounding number of those moviegoers polled stated they would return and would also recommend visiting Cinemark to a friend.

The health and safety of employees, guests and communities is a top priority. Cinemark Totem Lake and XD will open with The Cinemark Standard, greatly enhanced cleanliness, sanitizing and safety measures at every step of the moviegoing experience. Employees undergo extensive training on all new protocols and wear face masks while working, in addition to completing a wellness check-in prior to every shift. Each theatre also has a designated Chief Clean and Safety Monitor on duty to ensure the highest standards of safety, physical distancing, cleanliness and sanitization.

  • Each auditorium is extensively disinfected between showtimes with products identified by the EPA to be effective in eliminating COVID-19.
  • Theatres have staggered showtimes and limited capacities to maximize physical distancing.
  • Seat-Buffering Technology automatically blocks seats adjacent to a party upon ticket purchase.
  • Face masks are mandatory for all guests within the theatre and may only be removed for eating and drinking in the auditoriums. Face masks are required for all employees.
  • All public and high-touch spaces are thoroughly sanitized frequently.
  • Ample supplies of seat wipes and hand sanitizer are available for customer use.
  • Guests are encouraged to purchase tickets online and use contactless payment methods for a more contact-free experience.
  • Cinemark’s advanced, three-point air quality standard is designed to deliver an abundant supply of fresh outdoor air, maintain optimal circulation and eliminate pollutants.

    • Increased fresh-air rate. Cinemark is substantially raising the fresh-air rate of building HVAC systems by constantly utilizing supply fans to increase the total volume of fresh, outside air flowing into theatres.
    • Smart-flow air circulation design. Each auditorium within the theatre has its own HVAC system, which consistently diffuses fresh air from the ceiling down toward the floor where it is then returned to the filtration equipment, constantly refreshing the air.
    • Elimination of pollutants. Cinemark utilizes MERV filters in its HVAC systems to capture the majority of particles and pollutants.

Click here for Cinemark’s digital asset kit, including photos and b-roll of the exhibitor’s updated clean and safety protocols.

About Cinemark Holdings, Inc.:

Headquartered in Plano, TX, Cinemark (NYSE: CNK) is one of the largest and most influential movie theatre companies in the world. Cinemark’s circuit, comprised of various brands that also include Century, Tinseltown and Rave, operates 531 theatres (331 U.S., 200 South and Central America) with 5,958 screens (4,507 U.S., 1,451 South and Central America) in 42 states domestically and 15 countries throughout South and Central America. Cinemark consistently provides an extraordinary guest experience from the initial ticket purchase to the closing credits, including Movie Club, the first U.S. exhibitor-launched subscription program; the highest Luxury Lounger recliner seat penetration among the major players; XD – the No. 1 exhibitor-brand premium large format; and expansive food and beverage options to further enhance the moviegoing experience. For more information go to https://investors.cinemark.com/.

Media Contact:

Caitlin Piper

[email protected]

Investor Contact:

Chanda Brashears

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Film & Motion Pictures Entertainment

MEDIA:

Logo
Logo

Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer

  • Results from pre-planned subgroup analysis of stage III/IV newly diagnosed ovarian cancer patients with

    BRCA

    wild type (

    BRCA

    -wt) profile and homologous recombination proficiency (HRP) have been published in

    Gynecologic Oncology.
  • Patients treated with Vigil experienced improved overall survival (OS) and recurrence free survival (RFS) compared to placebo. No Grade 3 or 4 toxicities were observed in the Vigil-treated group.

DALLAS, March 26, 2021 (GLOBE NEWSWIRE) — Gradalis, Inc., a late clinical-stage company developing immunotherapies for multiple cancer indications, today announced that on March 12, 2021 Gynecologic Oncology published additional results from the VITAL clinical trial of gemogenovatucel-T (VigilTM) in ovarian cancer. These results provide evidence for the clinical utility of Vigil in Stage III/IV newly diagnosed ovarian cancer patients with BRCA wild-type molecular profile and homologous recombination proficient status.

Few treatment options exist for patients with homologous recombination proficient ovarian cancer. In particular, PARP inhibitors have not proven to be effective in this patient population.

Recently, Vigil showed significant clinical benefit with improvement in recurrence free (RFS) and overall survival (OS) in pre-planned subgroup analysis in Stage III/IV newly diagnosed ovarian cancer patients with the BRCA wild type (BRCA-wt) molecular profile. The newly published analysis further queried the homologous recombination (HR) status of patients enrolled in the VITAL study to determine clinical benefit of Vigil in HR proficient patients.

In the HR proficient subgroup, Vigil-treated patients experienced improved RFS (n = 25) compared to placebo (n = 20) (HR = 0.386; 90% CI 0.199–0.750; p = 0.007). Similarly, subgroup overall survival benefit was observed in the Vigil-treated group compared to placebo (HR = 0.342; 90% CI 0.141–0.832; p = 0.019). Vigil-treated patients did not experience any Grade 3/4 treatment-related toxicities.

“These data demonstrate that Vigil immunotherapy may provide clear clinical benefit to a patient population with limited therapeutic options,” Remarked John Nemunaitis, M.D., Chief Scientific Officer of Gradalis. “Vigil was well tolerated and effective in extending both overall survival and recurrence-free survival compared to placebo.”

Lead study investigator, Rodney P. Rocconi said, “As the field has become increasingly aware of specific molecular subgroups, we have been able to identify treatments with particular efficacy relative to alternatives. We are encouraged by these results in the HR -proficient ovarian cancer subgroup.”

Nemunaitis added, “These results published in Gynecologic Oncology provide additional clinical differentiation in a population with few therapeutic alternatives. We look forward to continued discussions on product registration with FDA.”

About Vigil

Vigil is a novel cancer cell immunotherapy that combines bi-shRNA furin, which blocks immunosuppressive protein production, with recombinant human GM-CSF, which stimulates the immune system. By utilizing the patient’s own tumor as the antigen source, Vigil is designed to elicit an immune response that is specifically targeted and broadly relevant to each patient’s unique tumor neoantigens. Vigil is being studied in ovarian cancer, Ewing’s sarcoma as well as gynecological cancers and advanced women’s cancer in combination with PD-L1 inhibitors.

About Ovarian Cancer

Ovarian cancer (OC) is a difficult and deadly disease that is typically diagnosed in advanced stages, and overall survival rates have held relatively steady over the past 20-30 years.

Ovarian cancer is the 5th deadliest cancer among women with over 22,000 new cases are reported each year in the US, of which approximately 85% are BRCA-wt disease status. Approximately 80% of cases are diagnosed at late stage III and IV. There are 14,000 deaths per year due to Ovarian Cancer in the US. Standard of care involves a debulking surgery and one or several rounds of chemotherapy.

Primary surgery and platinum-based chemotherapy is current standard of care. Despite this aggressive first line treatment, 60-75% of patients relapse within two years, median overall survival rate of less than 3 years. Even with increased diagnostic and treatment capabilities, there are not enough effective maintenance therapy options for all patients, particularly BRCA-wt and homologous recombination proficient (HRP) population (about 50% of all ovarian cancer patients).

About Gradalis

Gradalis is a late-stage biotechnology company focused on the development and commercialization of novel personalized therapeutics to treat cancer. We are focused on the development of the bi-shRNA platform that can be utilized to silence any gene or protein and applied to any cancer type. We utilized the bi-shRNA platform to develop Vigil, our proprietary personalized cancer in multiple advanced cancer indications with the lead program for the treatment of patients with Ovarian Cancer.

For additional information, please visit http://www.gradalisinc.com

Forward-looking statements

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Gradalis cautions investors not to rely too heavily on the forward-looking statements the company makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Gradalis undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact
Walter Chen
Gradalis, Inc.
Vice President – Finance & Corporate Development
+1 214 442 8170



Statement Pursuant to Section 19(a) of the Investment Company Act of 1940: DEX CUSIP #: 246060107

Statement Pursuant to Section 19(a) of the Investment Company Act of 1940: DEX CUSIP #: 246060107

PHILADELPHIA–(BUSINESS WIRE)–
On March 26, 2021, Delaware Enhanced Global Dividend and Income Fund (NYSE: DEX) (the “Fund”), a closed-end fund, paid a monthly distribution on its common stock of $0.0582 per share to shareholders of record at the close of business on March 19, 2021.

The following table sets forth the estimated amount of the sources of distribution for purposes of Section 19 of the Investment Company Act of 1940, as amended, and the related rules adopted thereunder. The Fund estimates the following percentages, of the total distribution amount per share, attributable to (i) net investment income, (ii) net realized short-term capital gain, (iii) net realized long-term capital gain and (iv) return of capital or other capital source. These percentages are disclosed for the current distribution as well as the fiscal year-to-date cumulative distribution amount per share for the Fund.

Current Distribution from:

 

 

 

 

Per Share ($)

 

%

Net Investment Income

0.0337

 

57.9%

Net Realized Short-Term Capital Gain

0.0000

 

0.0%

Net Realized Long-Term Capital Gain

0.0000

 

0.0%

Return of Capital or other Capital Source

0.0245

 

42.1%

Total (per common share)

0.0582

 

100.00%

 

 

 

 

Fiscal Year-to-Date Cumulative

 

 

 

Distributions from:

 

 

 

 

Per Share ($)

 

%

Net Investment Income

0.1006

 

44.6%

Net Realized Short-Term Capital Gain

0.0180

 

8.0%

Net Realized Long-Term Capital Gain

0.0053

 

2.4%

Return of Capital or other Capital Source

0.1013

 

45.0%

Total (per common share)

0.2252

 

100.00%

Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy. The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

Subject to the foregoing, the Fund estimates (as of the date hereof) that it has distributed more than its income and net realized capital gains for the fiscal year ending November 30, 2021; therefore, a portion of your distribution may be a return of capital. A return of capital may occur for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income.’

Presented below are return figures, based on the change in the Fund’s Net Asset Value per share (“NAV”), compared to the annualized distribution rate for this current distribution as a percentage of the NAV on the last business day of the month prior to distribution record date.

Fund Performance and Distribution Information

Fiscal Year to Date (12/01/2020 through 2/28/2021)

Annualized Distribution Rate as a Percentage of NAV^

6.57%

Cumulative Distribution Rate on NAV^^

2.12%

Cumulative Total Return on NAV*

4.00%

 

 

Average Annual Total Return on NAV for the 5-Year Period Ending 2/28/2021**

9.66%

 

 

^ Based on the Fund’s NAV as of February 28, 2021.

^^ Cumulative distribution rate is the cumulative amount of distributions paid during the Fund’s fiscal year ending November 30, 2021 based on the Fund’s NAV as of February 28, 2021.

*Cumulative total return is based on the change in NAV including distributions paid and assuming reinvestment of these distributions for the period December 1, 2020 through February 28, 2021.

**The 5-year average annual total return is based on change in NAV including distributions paid and assuming reinvestment of these distributions and is through the last business day of the month prior to the month of the current distribution record date.

While the NAV performance may be indicative of the Fund’s investment performance, it does not measure the value of a shareholder’s investment in the Fund. The value of a shareholder’s investment in the Fund is determined by the Fund’s market price, which is based on the supply and demand for the Fund’s shares in the open market.

About DEX

The Fund’s primary investment objective is to seek current income, with a secondary objective of capital appreciation. The Fund invests globally in dividend-paying or income-generating securities across multiple asset classes, including but not limited to: equity securities of large, well-established companies; securities issued by real estate companies (including real estate investment trusts and real estate industry operating companies); debt securities (such as government bonds; investment grade and high risk, high yield corporate bonds; and convertible bonds); and emerging market securities. The Fund also uses enhanced income strategies by engaging in dividend capture trading; option overwriting; and realization of gains on the sale of securities, dividend growth, and currency forwards. There is no assurance that the Fund will achieve its investment objectives.

Under normal market conditions, the Fund will invest: (1) at most 60% of its net assets in securities of U.S. issuers; and (2) at least 40% of its net assets in securities of non-U.S. issuers, unless market conditions are not deemed favorable by the Manager, in which case, the Fund would invest at least 30% of its net assets in securities of non-U.S. issuers; and (3) the Fund may invest up to 25% of its net assets in securities issued by real estate companies (including real estate investment trusts and real estate industry operating companies). In addition, the Fund utilizes leveraging techniques in an attempt to obtain higher return for the Fund.

The Fund has implemented a managed distribution policy. Under the policy, the Fund is managed with a goal of generating as much of the distribution as possible from net investment income and short-term capital gains. The balance of the distribution will then come from long-term capital gains to the extent permitted, and if necessary, a return of capital. Even though the Fund may realize current year capital gains, such gains may be offset, in whole or in part, by the Fund’s capital loss carryovers from prior years.

Currently under the Fund’s managed distribution policy, the Fund makes monthly distributions to common shareholders at a targeted annual distribution rate of 6.5% of the Fund’s average net asset value (“NAV”) per share. The Fund will calculate the average NAV per share from the previous three full months immediately prior to the distribution based on the number of business days in those three months on which the NAV is calculated. The distribution will be calculated as 6.5% of the prior three month’s average NAV per share, divided by 12. The Fund will generally distribute amounts necessary to satisfy the Fund’s managed distribution policy and the requirements prescribed by excise tax rules and Subchapter M of the Internal Revenue Code. This distribution methodology is intended to provide shareholders with a consistent, but not guaranteed, income stream and a targeted annual distribution rate and is intended to narrow the discount between the market price and the NAV of the Fund’s common shares, but there is no assurance that the policy will be successful in doing so. The methodology for determining monthly distributions under the Fund’s managed distribution policy will be reviewed at least annually by the Fund’s Board of Trustees, and the Fund will continue to evaluate its distribution in light of ongoing market conditions.

The payment of dividend distributions in accordance with the managed distribution policy may result in a decrease in the Fund’s net assets. A decrease in the Fund’s net assets may cause an increase in the Fund’s annual operating expenses and a decrease in the Fund’s market price per share to the extent the market price correlates closely to the Fund’s net asset value per share. The managed distribution policy may also negatively affect the Fund’s investment activities to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must liquidate securities that it would not have sold, for the purpose of paying the dividend distribution. The managed distribution policy may, under certain circumstances, cause the amounts of taxable distributions to exceed the amount minimally required to be distributed under the tax rules, such excess will be taxable as ordinary income to the extent loss carry forwards reduce the required amount of capital gains distributions in that year. Investors should consult their tax advisor regarding federal, state, and local tax considerations that may be applicable in their particular circumstances.

About Macquarie Investment Management

Macquarie Investment Management, a member of Macquarie Group, includes the former Delaware Investments and is a global asset manager with offices throughout the United States, Europe, Asia, and Australia. As active managers, we prioritize autonomy and accountability at the team level in pursuit of opportunities that matter for clients. Macquarie Investment Management is supported by the resources of Macquarie Group (ASX: MQG; ADR: MQBKY), a global provider of asset management, investment, banking, financial and advisory services.

Advisory services are provided by Macquarie Investment Management Business Trust, a registered investment advisor. Macquarie Group refers to Macquarie Group Limited and its subsidiaries and affiliates worldwide. For more information about Delaware Funds® by Macquarie, visit delawarefunds.com or call 800 523-1918.

Other than Macquarie Bank Limited (MBL), none of the entities referred to in this document are authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia). The obligations of these entities do not represent deposits or other liabilities of MBL, a subsidiary of Macquarie Group Limited and an affiliate of Macquarie Investment Management. MBL does not guarantee or otherwise provide assurance in respect of the obligations of these entities, unless noted otherwise.

Investors

Computershare

866 437-0252

delawarefunds.com/closed-end

Media contacts

Daniela Palmieri

215 255-8878

Jessica Fitzgerald

215 255-1336

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Consulting Banking Professional Services Finance

MEDIA:

Heart2Heart CPR Shines a Light on Sudden Unexpected Death in Epilepsy (SUDEP) by Sharing Kayla’s Story

Today is Epilepsy Awareness Day

TORONTO, March 26, 2021 (GLOBE NEWSWIRE) — Heart to Heart First Aid CPR Services Inc., has been in the business of saving lives for 21 years. They instill valuable first aid and CPR knowledge and skills to their clients. They also create awareness on new and relevant topics and trends in health and safety. In recognition of Epilepsy Awareness Day, Heart to Heart, is informing the public about a rare life threatening medical condition called Sudden Unexpected Death in Epilepsy (SUDEP). If you or someone you know has epilepsy or experiences seizures, please listen to Kayla’s story. It may save the life of someone you love.

A media snippet accompanying this announcement is available by clicking the image or link below: 

Kayla’s Story: The things Kayla loved the most – family, dancing and acrobatics.

On the morning of February 11th, 2019, Kayla entered her parents’ bedroom. She told them she had a bad dream. Climbing into her parents’ bed, she fell asleep with her father while her mother, Geri, got ready for work.

After Geri left for work, Kayla’s father awoke to discover his daughter having her first seizure. On April 8th and 9th, 2019, within 30 to 45 minutes after going to sleep, Kayla had her 2nd and 3rd seizure.

Kayla underwent physical examinations, laboratory work, and a sleep deprivation test. Kayla’s test results came back negative. No formal diagnosis provided. Kayla’s doctor felt it was best to prescribe a low dose anti-seizure medication and to be monitored for one year.

For the next 8 months, Kayla was seizure-free, and it seemed that the medication was working. Kayla, by all accounts, was a very happy, healthy and extremely athletic young girl. She had a passion for competitive dance and acrobatics. Life was pretty normal, that is, until that dreadful night in December. A night that would change everything forever.

On December 12, 2019, in the middle of the night while Kayla was sleeping, she had another seizure. One that she would not overcome. Sadly, Kayla passed away sometime during the night.   When her mother tried to wake Kayla up for school, the following morning, she found Kayla unresponsive and not breathing. Despite the best efforts of Geri and Guelph EMS to resuscitate Kayla, she was already passed.

When the post-mortem report came back, it confirmed the cause of death was SUDEP. Sudden Unexpected Death in Epilepsy. How could this be? Kayla had never been diagnosed with Epilepsy.

WATCH KAYLA’S FULL STORY HERE – 4 MINUTE VIDEO

Each year 1 in 1,000 adults, and 1 in 4,500 children with Epilepsy die from SUDEP. This is most likely a low estimate due to poor case identification and lack of awareness. The cause of SUDEP is unknown. It usually occurs at night or during sleep, thus making it difficult to determine exactly what happened during the last moments of life.

“A seizure can shut down the brain, including the center that controls respiration. If a person is sleeping and lying face down, death may occur,” said Dr. Orrin Devinsky, director of NYU Comprehensive Epilepsy Center in Manhattan.

“Many doctors do not warn patients and their families about SUDEP. There are things that patients and their families can do to lower it,” Dr. Devinsky said. One is to be vigilant about taking medication to control seizures. Another example may include using monitoring devices to detect seizures during the night.

“About 70 percent of cases occur during sleep, and the people are often found face down in bed. Usually, they have been sleeping alone”, Dr. Devinsky said. “Seizures can also impair the arousal reflex. This causes people to move or shift positions during sleep if their air supply is blocked. In this case, if someone else is present and can roll the person over or try to rouse them, that can be lifesaving,” Dr. Devinsky said.

“It can happen to anyone with Epilepsy. Even the first seizure could be the last one. The more uncontrolled the seizures, the more severe, and the more they occur in sleep, the higher the risk,” he said.

While not as common in children, SUDEP is a preventable cause of death during childhood. A Canadian Pediatric Surveillance Program is a current study that investigates the incidence and risk factors for SUDEP in Canadian children. 

Heart 2 Heart First Aid & CPR Inc., believes research is needed to help those with Epilepsy understand how to lower their risk of SUDEP. An awareness campaign on Sudden Unexpected Death in Epilepsy (SUDEP), will take place immediately and this topic will be covered in all Heart to Heart’s courses. This includes Standard First Aid CPR, Emergency First Aid CPR, Basic Life Support,Instructor Development and Professional Responder programs. This initiative will be offered to all clients, across all 17 training locations nationwide.

“Kayla’s story and legacy has really touched us here at Heart to Heart First Aid CPR Services. We want to support the Chadwick family and get the message out. We are confident that Kayla’s story will save countless lives as we bring more awareness to this life-threatening condition,” says Nick Rondinelli, CEO of Heart to Heart First Aid CPR Services. Her life, although short, will have a significant impact to all those who learn about SUDEP for years to come.

Please support Kayla’s cause today as we mark Epilepsy Awareness Day. Even a small donation of $25, $50 can have a significant impact.

The Make your Mark Foundation was created in memory of Kayla Chadwick by her family. We hope that by sharing Kayla’s story we can both raise awareness and encourage research into Epilepsy and SUDEP. All funds raised will support research dedicated to Epilepsy and SUDEP throughout Canada.

Make your mark and donate today: https://www.canadahelps.org/en/dn/60291

By Nick Rondinelli – CEO / Owner

Heart to Heart First Aid CPR Services Inc.

Direct: 416-833-0421 – Office: 416-960-5319
[email protected]www.heart2heartcpr.com


https://www.facebook.com/Heart2HeartFirstAidCPR/

https://twitter.com/hearttoheartcpr

https://www.linkedin.com/in/nick-rondinelli-44123414/

https://www.youtube.com/channel/UCMjeE4DusAj8NIaKjhMAQaQ/videos

https://www.instagram.com/heart2heartcpr/

Recipient of the Rescuers Award and Proud Canadian Red Cross Training Partner

CONTACT: Nick Rondinelli – CEO

COMPANY: Heart2Heart CPR

PHONE: 416-833-0421

EMAIL:

[email protected]


WEB:

www.heart2heartcpr.com



Statement Pursuant to Section 19(a) of the Investment Company Act of 1940: DDF

Statement Pursuant to Section 19(a) of the Investment Company Act of 1940: DDF

CUSIP #: 245915103

PHILADELPHIA–(BUSINESS WIRE)–
On March 26, 2021, Delaware Investments Dividend and Income Fund, Inc. (NYSE: DDF) (the “Fund”), a closed-end fund, paid a monthly distribution on its common stock of $0.0623 per share to shareholders of record at the close of business on March 19, 2021.

The following table sets forth the estimated amount of the sources of distribution for purposes of Section 19 of the Investment Company Act of 1940, as amended, and the related rules adopted thereunder. The Fund estimates the following percentages, of the total distribution amount per share, attributable to (i) net investment income, (ii) net realized short-term capital gain, (iii) net realized long-term capital gain and (iv) return of capital or other capital source. These percentages are disclosed for the current distribution as well as the fiscal year-to-date cumulative distribution amount per share for the Fund.

Current Distribution from:

 

 

 

Per Share ($)

%

Net Investment Income

0.0269

43.2%

Net Realized Short-Term Capital Gain

0.0354

56.8%

Net Realized Long-Term Capital Gain

0.0000

0.0%

Return of Capital or other Capital Source

0.0000

0.0%

Total (per common share)

0.0623

100.00%

 

 

 

Fiscal Year-to-Date Cumulative

 

 

Distributions from:

 

 

 

Per Share ($)

%

Net Investment Income

0.0934

39.2%

Net Realized Short-Term Capital Gain

0.0867

36.5%

Net Realized Long-Term Capital Gain

0.0315

13.2%

Return of Capital or other Capital Source

0.0265

11.1%

Total (per common share)

0.2381

100.00%

Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy. The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

Subject to the foregoing, the Fund estimates (as of the date hereof) that it has distributed more than its income and net realized capital gains for the fiscal year ending November 30, 2021; therefore, a portion of your distribution may be a return of capital. A return of capital may occur for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income.’

Presented below are return figures, based on the change in the Fund’s Net Asset Value per share (“NAV”), compared to the annualized distribution rate for this current distribution as a percentage of the NAV on the last business day of the month prior to distribution record date.

Fund Performance & Distribution Information

Fiscal Year to Date (12/01/2020 through 2/28/2021)

Annualized Distribution Rate as a Percentage of NAV^

7.49%

Cumulative Distribution Rate on NAV^^

2.39%

Cumulative Total Return on NAV*

6.24%

 

 

Average Annual Total Return on NAV for the 5 Year Period Ending 2/28/2021**

9.49%

 

 

^ Based on the Fund’s NAV as of February 28, 2021.

^^ Cumulative distribution rate is the cumulative amount of distributions paid during the Fund’s fiscal year ending November 30, 2021 based on the Fund’s NAV as of February 28, 2021.

*Cumulative total return is based on the change in NAV including distributions paid and assuming reinvestment of these distributions for the period December 1, 2020 through February 28, 2021.

**The 5 year average annual total return is based on change in NAV including distributions paid and assuming reinvestment of these distributions and is through the last business day of the month prior to the month of the current distribution record date.

While the NAV performance may be indicative of the Fund’s investment performance, it does not measure the value of a shareholder’s investment in the Fund. The value of a shareholder’s investment in the Fund is determined by the Fund’s market price, which is based on the supply and demand for the Fund’s shares in the open market.

About DDF

The Fund’s primary investment objective is to seek high current income; capital appreciation is a secondary objective. The Fund seeks to achieve its objectives by investing, under normal circumstances, at least 65% of its total assets in income-generating equity securities, including dividend-paying common stocks, convertible securities, preferred stocks, and other equity-related securities, which may include up to 25% in real estate investment trusts (REITs) and real estate industry operating companies. Up to 35% of the Fund’s total assets may be invested in nonconvertible debt securities consisting primarily of high-yield, high-risk corporate bonds. In addition, the Fund utilizes leveraging techniques in an attempt to obtain a higher return for the Fund. There is no assurance that the Fund will achieve its investment objectives.

The Fund has implemented a managed distribution policy. Under the policy, the Fund is managed with a goal of generating as much of the distribution as possible from net investment income and short-term capital gains. The balance of the distribution will then come from long-term capital gains to the extent permitted, and if necessary, a return of capital. Even though the Fund may realize current year capital gains, such gains may be offset, in whole or in part, by the Fund’s capital loss carryovers from prior years.

Currently under the Fund’s managed distribution policy, the Fund makes monthly distributions to common shareholders at a targeted annual distribution rate of 7.5% of the Fund’s average net asset value (“NAV”) per share. The Fund will calculate the average NAV per share from the previous three full months immediately prior to the distribution based on the number of business days in those three months on which the NAV is calculated. The distribution will be calculated as 7.5% of the prior three month’s average NAV per share, divided by 12. The Fund will generally distribute amounts necessary to satisfy the Fund’s managed distribution policy and the requirements prescribed by excise tax rules and Subchapter M of the Internal Revenue Code. This distribution methodology is intended to provide shareholders with a consistent, but not guaranteed, income stream and a targeted annual distribution rate and is intended to narrow the discount between the market price and the NAV of the Fund’s common shares, but there is no assurance that the policy will be successful in doing so. The methodology for determining monthly distributions under the Fund’s managed distribution policy will be reviewed at least annually by the Fund’s Board of Directors, and the Fund will continue to evaluate its distribution in light of ongoing market conditions.

The payment of dividend distributions in accordance with the managed distribution policy may result in a decrease in the Fund’s net assets. A decrease in the Fund’s net assets may cause an increase in the Fund’s annual operating expenses and a decrease in the Fund’s market price per share to the extent the market price correlates closely to the Fund’s net asset value per share. The managed distribution policy may also negatively affect the Fund’s investment activities to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must liquidate securities that it would not have sold, for the purpose of paying the dividend distribution. The managed distribution policy may, under certain circumstances, cause the amounts of taxable distributions to exceed the amount minimally required to be distributed under the tax rules, such excess will be taxable as ordinary income to the extent loss carry forwards reduce the required amount of capital gains distributions in that year. Investors should consult their tax advisor regarding federal, state, and local tax considerations that may be applicable in their particular circumstances.

About Macquarie Investment Management

Macquarie Investment Management, a member of Macquarie Group, includes the former Delaware Investments and is a global asset manager with offices throughout the United States, Europe, Asia, and Australia. As active managers, we prioritize autonomy and accountability at the team level in pursuit of opportunities that matter for clients. Macquarie Investment Management is supported by the resources of Macquarie Group (ASX: MQG; ADR: MQBKY), a global provider of asset management, investment, banking, financial and advisory services.

Advisory services are provided by Macquarie Investment Management Business Trust, a registered investment advisor. Macquarie Group refers to Macquarie Group Limited and its subsidiaries and affiliates worldwide. For more information about Delaware Funds® by Macquarie, visit delawarefunds.com or call 800 523-1918.

Other than Macquarie Bank Limited (MBL), none of the entities referred to in this document are authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia). The obligations of these entities do not represent deposits or other liabilities of MBL, a subsidiary of Macquarie Group Limited and an affiliate of Macquarie Investment Management. MBL does not guarantee or otherwise provide assurance in respect of the obligations of these entities, unless noted otherwise.

Investors

Computershare

866 437-0252

delawarefunds.com/closed-end

Media contacts

Daniela Palmieri

215 255-8878

Jessica Fitzgerald

215 255-1336

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Macquarie Global Infrastructure Total Return Fund Inc.

Macquarie Global Infrastructure Total Return Fund Inc.

CUSIP #: 55608D101

Statement Pursuant to Section 19(a) of the Investment Company Act of 1940

NEW YORK–(BUSINESS WIRE)–
Macquarie Global Infrastructure Total Return Fund Inc. (NYSE: MGU) (the “Fund”), a closed-end fund, paid a monthly distribution on its common stock of $0.0750 per share to shareholders of record at the close of business on March 19, 2021.

The following table sets forth the estimated amount of the sources of distribution for purposes of Section 19 of the Investment Company Act of 1940, as amended, and the related rules adopted thereunder. The Fund estimates the following percentages, of the total distribution amount per share, attributable to (i) current and prior fiscal year net investment income, (ii) net realized short-term capital gain, (iii) net realized long-term capital gain and (iv) return of capital or other capital source as a percentage of the total distribution amount. These percentages are disclosed for the current distribution as well as the fiscal year-to-date cumulative distribution amount per share for the Fund.

Current Distribution from:

 

 

 

 

Per Share ($)

 

%

Net Investment Income

0.0390

 

52.00%

Net Realized Short-Term Capital Gain

0.0360

 

48.00%

Net Realized Long-Term Capital Gain

0.0000

 

0.00%

Return of Capital or other Capital Source

0.0000

 

0.00%

Total (per common share)

0.0750

 

100.00%

 

 

 

 

Fiscal Year-to-Date Cumulative

 

 

 

Distributions from:

 

 

 

 

Per Share ($)

 

%

Net Investment Income

0.1221

 

40.70%

Net Realized Short-Term Capital Gain

0.1779

 

59.30%

Net Realized Long-Term Capital Gain

0.0000

 

0.00%

Return of Capital or other Capital Source

0.0000

 

0.00%

Total (per common share)

0.3000

 

100.00%

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and not for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

Presented below are return figures, based on the change in the Fund’s Net Asset Value per share (“NAV”), compared to the annualized distribution rate for this current distribution as a percentage of the NAV on the last business day of the month prior to distribution record date.

Fund Performance & Distribution Information

Fiscal Year to Date (12/01/2020 through 2/28/2021)

Annualized Distribution Rate as a Percentage of NAV^

3.76%

Cumulative Distribution Rate on NAV^^

1.25%

Cumulative Total Return on NAV*

0.43%

 

 

Average Annual Total Return on NAV for the 5 Year Period Ending 2/28/2021**

8.35%

 

 

^ Based on the Fund’s NAV as of February 28, 2021.

^^ Cumulative distribution rate is the cumulative amount of distributions paid during the Fund’s fiscal year ending November 30, 2021 based on the Fund’s NAV as of February 28, 2021.

*Cumulative total return is based on the change in NAV including distributions paid and assuming reinvestment of these distributions for the period December 1, 2020 through February 28, 2021.

**The 5 year average annual total return is based on change in NAV including distributions paid and assuming reinvestment of these distributions and is through the last business day of the month prior to the month of the current distribution record date.

The payment of dividend distributions in accordance with the distribution policy may result in a decrease in the Fund’s net assets. A decrease in the Fund’s net assets may cause an increase in the Fund’s annual operating expenses and a decrease in the Fund’s market price per share to the extent the market price correlates closely to the Fund’s net asset value per share. The distribution policy may also negatively affect the Fund’s investment activities to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must liquidate securities that it would not have sold, for the purpose of paying the dividend distribution. The distribution policy may, under certain circumstances, cause the amounts of taxable distributions to exceed the amount minimally required to be distributed under the tax rules, such excess will be taxable as ordinary income to the extent loss carry forwards reduce the required amount of capital gains distributions in that year. The Board of Directors has the right to amend, suspend or terminate the distribution policy at any time. The amendment, suspension or termination of the distribution policy may affect the Fund’s market price per share. Investors should consult their tax advisor regarding federal, state, and local tax considerations that may be applicable in their particular circumstances.

While the NAV performance may be indicative of the Fund’s investment performance, it does not measure the value of a shareholder’s investment in the Fund. The value of a shareholder’s investment in the Fund is determined by the Fund’s market price, which is based on the supply and demand for the Fund’s shares in the open market. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s Managed Distribution Plan.

Furthermore, the Board of Directors reviews the amount of any potential distribution and the income, capital gain or capital available. The Board of Directors will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the financial market environment. The Fund’s distribution policy is subject to modification by the Board of Directors at any time. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

The Fund is not intended to be a complete investment program. An investment in the Fund involves risks, and the Fund may or may not be able to achieve its investment objective for a variety of reasons. The following summarizes some of the Fund’s risks but does not purport to be a complete listing of all of the risks. Investors should carefully review the Fund’s Prospectus and consult their own advisers.

The Fund is also subject to risk because it is an actively managed portfolio. Industry Concentration and Infrastructure Industry Risk. The Fund will be concentrated in the infrastructure industry, and will be more susceptible to adverse economic or regulatory occurrences affecting that industry than a fund that is not concentrated in a specific industry. Non-U.S. Investment Risk. A majority of the Fund’s investments will be in non-U.S. issuers and a substantial portion of the trades executed for the Fund will take place on foreign exchanges. Investments in securities and instruments of non-U.S. issuers involve certain considerations and risks not ordinarily associated with investments in those of U.S. issuers. Emerging Markets Risk. In addition to non-US investment risk, investments in emerging markets may expose the Fund to heightened risks that may be more volatile than investments in developed markets. Use of Derivatives and Hedging. The Fund may use derivatives and employ a variety of hedging techniques. Derivatives can be illiquid, may disproportionately increase losses and may have a potentially large impact on the Fund’s performance. Certain of the investment techniques that the Fund may employ for hedging or to increase income or total return will expose the Fund to additional risks. Leverage Risk. The Fund expects to employ leverage as part of its investing strategy. The use of leverage will increase the volatility of the Fund and increase risk to investors. Any difficulty in maintaining the Fund’s leverage could cause a diversion of cash flow and/or require liquidation of some portion of the Fund’s portfolio. Restrictions imposed as a result of any leverage may directly or indirectly inhibit the Fund’s ability to take actions that otherwise may be taken in an unleveraged portfolio of similar assets.

Other than Macquarie Bank Limited (MBL), none of the entities noted are authorized deposit-taking institution for the purposes of the Banking Act 1959 (Commonwealth of Australia). The obligations of these entities do not represent deposits or other liabilities of MBL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of these entities, unless noted otherwise.

Investor/Broker Inquiries

Tel: 866 567-4771

E-mail: [email protected]

Web:www.macquarieim.com/mgu

Media Inquiries

Daniela Palmieri

215 255-8878

[email protected]

Jessica Fitzgerald

215 255-1336

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services

MEDIA:

[Correction] GOGL – Special General Meeting

26.03.2021

Golden Ocean Group Limited (the “Company”) advises that a Special General Meeting of the Shareholders of the Company was held on March 26, 2021 at 9:00 a.m. at Par-la-Ville Place, 4th Floor, 14 Par-la-Ville Road, Hamilton, Bermuda (the “Meeting”). The following resolution was in line with the proposal in the notice to the Meeting.

The Company’s authorized share capital be increased from US$10,000,000.00 divided into 200,000,000 common shares of US$0.05 par value each to US$15,000,000.00 divided into 300,000,000 common shares of US$0.05 par value each by the creation of 100,000,000 common shares of US$0.05 par value each.

Hamilton, Bermuda
March 26, 2021

 



Lassonde Industries Inc. Appoints Future President and Chief Operating Officer and Announces Fourth Quarter and Fiscal 2020 Results

Canada NewsWire

ROUGEMONT, QC, March 26, 2021 /CNW/ – Lassonde Industries Inc. (TSX: LAS.A) (“Lassonde”) announced today that profit attributable to the Company’s shareholders for fiscal 2020 was up 35.9%.

Lassonde also announced the appointment of Mr. Vincent R. Timpano to succeed Mr. Jean Gattuso as President and Chief Operating Officer of Lassonde as of October 1, 2021. Lassonde has previously announced that in accordance with its succession plan, Mr. Gattuso indicated his decision to step down on September 30, 2021.

Since his appointment in September 2020 as President and Chief Executive Officer of Lassonde Pappas and Company Inc. (“LPC,”), Lassonde’s largest manufacturing and sales subsidiary of ready-to-drink juices and drinks, Mr. Timpano took on the oversight of the strategic growth and development of our U.S. operations. During the six-month transition period provided for in the Corporation’s succession plan, he will benefit from the support of the Corporation’s executive team as he transitions to his new set of responsibilities, while Mr. Gattuso maintains his current role until September 30, 2021.

“The choice of Mr. Timpano as successor was clear because of his leadership, his expertise in the area of consumer products, his success managing LPC and his alignment with our values. He will succeed Mr. Gattuso who, over the last 34 years with Lassonde, contributed exceptionally to the growth and expansion of the Corporation on both sides of the border. This transition between executive officers will ensure continuity of a proven business model,” said Nathalie Lassonde, Chief Executive Officer and Vice Chairman of the Board of Directors and Pierre-Paul Lassonde, Chairman of the Board of Directors.

Vincent R. Timpano will soon join Lassonde’s management team at the Rougemont head office, from where he will be carrying out his duties.

“I am excited about the prospect of working with Nathalie Lassonde and the rest of the management team to continue implementing the Corporation’s business strategy. Lassonde has a strong entrepreneurial spirit, a portfolio of quality brands and a sound financial position,” said Mr. Timpano.

Mr. Timpano has a solid track record as a corporate officer with extensive commercial and operational experience. Over the past 20 years, he has served in various executive roles, including President, Global Coalitions at Aimia Inc., President of Coca-Cola Canada and President and Chief Executive Officer of The Minute Maid Company Canada. In addition, Mr. Timpano has served on numerous boards, including as Chair, with United Way Toronto. He currently serves on the board of advisors with The Napoleon Group of Companies.

Mr. Timpano is a graduate of the Institute of Corporate Directors, Rotman School of Management of the University of Toronto and received an MBA from the Ivey Business School of the University of Western Ontario.


Fiscal 2020

Lassonde posted sales of $1,980.9 million in 2020, up 18.0% from $1,678.3 million in 2019. Excluding the $175.4 million in sales from Sun-Rype, an entity acquired on January 3, 2020, and a $13.3 million favourable foreign exchange impact, adjusted sales were up 6.8% year over year. The 2020 profit attributable to the Company’s shareholders totalled $97.6 million compared to $72.0 million last year. Excluding the impacts of the Sun-Rype acquisition and of a gain of $13.8 million, net of tax, realized in 2019 following the settlement of an insurance claim, the 2020 profit attributable to the Company’s shareholders was up $34.5 million year over year.


Financial highlights


(in thousands of dollars)


Fourth quarters


ended


Years


ended


December
 
31, 2020

December 31, 2019


Dec
ember 31, 2020

December 31, 2019

Sales


$


515,065

$

432,127


$


1,980,925

$

1,678,301

Operating profit


38,907

24,964


151,931

100,826

Profit before income taxes


33,815

40,694


134,592

100,488

Profit attributable to the Company’s
shareholders


23,538

28,466


97,816

71,977

Basic and diluted earnings per
share (in $)


$

 


3.39

$

 

4.10

 


$

 


14.11

 

$

 

10.37



Note:

These are financial highlights only. Management’s Discussion and Analysis and the audited consolidated financial statements and notes thereto for the year ended December 31, 2020 are available on the SEDAR website at www.sedar.com and on the website of Lassonde Industries Inc.

“Industry volumes as well as our sales increased significantly in 2020. While this is a significant progression, we believe it is too early to conclude that this is a sustainable phenomenon. We are particularly pleased with our improved profitability, which is the result of good performance in all our business units. Demand for our products remains strong and we are striving to meet this demand despite the constrained availability of labour due to the need to maintain a safe environment for all our employees in the context of the ongoing pandemic. I would like to take this opportunity to thank our employees for their exceptional work during these difficult times,” said Nathalie Lassonde, Chief Executive Officer and Vice Chairman of the Board of Directors of Lassonde Industries Inc.


2020 Financial Results

On January 3, 2020, the Company completed the acquisition of Sun-Rype Products Ltd. and of two of its affiliates (“Sun-Rype”) for a cash consideration of $89.3 million that was paid at the close of the transaction. This amount included preliminary adjustments related to cash, working capital, and property, plant and equipment. During the second quarter of 2020, an amount of $2.2 million was received from the seller following the final settlement of these adjustments. As part of the transaction, the Company assumed liabilities of $23.0 million related to lease liabilities for the Sun-Rype facilities. The acquisition was financed by the Company’s existing Canadian credit facility. The transaction costs, incurred mainly in the fourth quarter of 2019, were $1.5 million. The Company has recognized this business combination using the acquisition method in accordance with the provisions of IFRS 3. Therefore, the 2020 consolidated financial statements include the results of Sun-Rype from January 3, 2020.

For 2020, the Company’s sales totalled $1,980.9 million, up $302.6 million or 18.0% from $1,678.3 million in 2019. Sales from Sun-Rype added $175.4 million to the Company’s 2020 sales. Excluding Sun-Rype’s sales and a $13.3 million favourable foreign exchange impact, the Company’s sales were up $113.9 million or 6.8% year over year. This increase was largely due to an increase in sales of private label products. The Company believes that a significant portion of this increase could be due to changes in food habits related to the impacts of COVID–19, as industry sales volumes have also benefited from a notable increase.

The Company’s 2020 operating profit totalled $151.9 million, up $51.1 million from $100.8 million last year. During 2020, Sun-Rype posted $8.2 million in operating profit whereas in 2019, the Company had incurred $1.5 million in expenses related to the Sun-Rype acquisition. Excluding these items, the Company’s operating profit was up $41.4 million year over year. This increase was explained by higher gross margins from the Company’s U.S. and Canadian operations, mainly due to a favourable change in the sales mix, to an increase in sales volume and to a decrease in the cost of certain raw materials, especially orange concentrate and the resin used to manufacture plastic bottles (“PET resin”), partly offset by additional production costs related to the pandemic. The operating profit was also affected by higher performance related salary expenses and an increase in warehousing and transportation costs, partly offset by lower selling and marketing expenses.

The Company’s financial expenses went from $19.5 million in 2019 to $17.3 million in 2020. Excluding $2.7 million in interest expense related to the Sun-Rype acquisition, financial expenses were down $4.9 million. This decrease was essentially due to a reduction in the interest expense on long-term debt explained by lower debt levels resulting from a significant cash flow generation in 2020. 

“Other (gains) losses” went from a $19.2 million gain in 2019 to a $0.8 million gain in 2020. This 2020 gain was due to $0.6 million in gains realized following the settlement of various insurance claims and to a $0.2 million gain resulting from a change in the fair value of financial instruments, whereas the 2019 gain was mainly due to a $20.8 million gain realized following the settlement of an insurance claim directly related to the acquisition price of Old Orchard Brands, LLC (“OOB”), partly offset by a $1.0 million loss resulting from a change in the fair value of financial instruments and by $0.8 million in foreign exchange losses.

Profit before income taxes stood at $134.6 million in 2020, up $34.1 million from $100.5 million in 2019.

Income tax expense went from $25.5 million in 2019 to $32.7 million in 2020. At 24.3%, the 2020 effective income tax rate was lower than the 25.4% rate in 2019. The 2019 effective income tax rate reflected the unfavourable impact of changes to U.S. tax regulations affecting the deductibility of certain interest expenses. Excluding this item, the 2020 effective income tax rate was similar to the adjusted rate in 2019 and mainly reflects a decrease in the deductible amounts on the Company’s interest expense offset by the impact of incentive measures adopted by the U.S. government to help businesses deal with the COVID-19 crisis.

The 2020 profit totalled $101.9 million, up $27.0 million from $74.9 million in 2019. The current results include a profit of $5.6 million from Sun-Rype and an amount of $1.3 million, net of tax, in additional financial expenses related to the financing of the Sun-Rype acquisition while the 2019 profit included a $15.3 million gain, net of tax, realized following the settlement of an insurance claim and $1.1 million, net of tax, in Sun-Rype acquisition-related costs. Excluding these items, the Company’s 2020 profit was up $36.9 million year over year.

Profit attributable to the Company’s shareholders was $97.8 million, resulting in basic and diluted earnings per share of $14.11 for 2020. In 2019, profit attributable to the Company’s shareholders had totalled $72.0 million, resulting in basic and diluted earnings per share of $10.37. Excluding the impacts of the Sun-Rype acquisition and of the gain realized in 2019 following the settlement of an insurance claim, the 2020 profit attributable to the Company’s shareholders was up $34.5 million year over year.

The Company’s operating activities generated $231.2 million in cash during 2020, while they had generated $140.7 million in cash during 2019. As for Sun-Rype’s operating activities, they generated $16.5 million in cash during 2020. Financing activities used $92.6 million in cash during 2020, while they had used $100.7 million in 2019. Investing activities used $121.0 million in cash during 2020 compared to $55.3 million used in 2019. At year-end 2020, the Company reported a cash and cash equivalents balance of $6.8 million and no bank overdraft, whereas, at the end of 2019, the cash and cash equivalents balance was $1.8 million and the bank overdraft balance was $12.4 million.


Fourth Quarter Financial Results

For the fourth quarter of 2020, the Company’s sales totalled $515.1 million, up $83.0 million or 19.2% from $432.1 million in the fourth quarter of 2019. Sun–Rype’s fourth-quarter sales totalled $48.1 million, leaving a $34.9 million favourable variance on a comparable basis. This increase was mainly due to an increase in sales of private label products and to the favourable impact of selling price adjustments on national brand sales.

The Company’s operating profit for the fourth quarter of 2020 totalled $38.9 million, up $13.9 million from $25.0 million in the same quarter last year. During the fourth quarter of 2020, Sun-Rype posted $1.7 million in operating profit whereas in 2019, the Company had incurred $1.5 million in expenses related to the Sun-Rype acquisition. Excluding these items, the Company’s operating profit was up $10.7 million year over year. The increase came from higher gross margin from the Company’s Canadian operations, mainly due to selling price adjustments, partly offset by higher performance-related salary expenses and by an increase in marketing expenses in Canada.

The Company’s financial expenses went from $5.1 million in the fourth quarter of 2019 to $3.7 million in the fourth quarter of 2020. Excluding $0.5 million in interest expense related to the Sun-Rype acquisition, financial expenses were down $1.9 million. This decrease was essentially due to a decrease in the interest expense on long-term debt. 

“Other (gains) losses” went from a $20.9 million gain in the fourth quarter of 2019 to a $1.2 million loss in the fourth quarter of 2020. This 2020 fourth-quarter loss was essentially due to $1.8 million in foreign exchange losses, partly offset by $0.4 million in gains realized following the settlement of various insurance claims, whereas the 2019 fourth-quarter gain was mainly due to a $20.8 million gain realized following the settlement of an insurance claim directly related to the OOB acquisition price.

Profit before income taxes stood at $33.8 million in the fourth quarter of 2020, down $6.9 million from $40.7 million in the fourth quarter of 2019. 

Income tax expense went from $10.3 million in the fourth quarter of 2019 to $9.6 million in the fourth quarter of 2020. At 28.3%, the 2020 fourth quarter effective income tax rate was higher than the 25.4% rate in the same quarter of 2019. The 2019 fourth-quarter effective income tax rate reflected the unfavourable impact of changes to U.S. tax regulations affecting the deductibility of certain interest expenses and special taxes related thereto. Excluding this item, the 2020 fourth-quarter higher effective income tax rate mainly reflects a decrease in the deductible amounts on the Company’s interest expense, adjustments resulting from an unfavourable variance of the geographic distribution of the Company’s profit before income taxes and a U.S. withholding tax related to an intercompany dividend. 

The 2020 fourth-quarter profit totalled $24.3 million, down $6.1 million from $30.4 million in the fourth quarter of 2019. The current quarter’s results include a profit of $1.2 million from Sun-Rype and an amount of $0.2 million, net of tax, in additional financial expenses related to the financing of the Sun-Rype acquisition while the 2019 fourth-quarter profit included a $15.3 million gain, net of tax, realized following the settlement of an insurance claim and $1.1 million, net of tax, in Sun-Rype acquisition-related costs. Excluding these items, the Company’s 2020 fourth–quarter profit was up $7.1 million year over year. 

Profit attributable to the Company’s shareholders was $23.5 million, resulting in basic and diluted earnings per share of $3.39 for the fourth quarter of 2020. In the fourth quarter of 2019, profit attributable to the Company’s shareholders had totalled $28.5 million, resulting in basic and diluted earnings per share of $4.10. Excluding the impacts of the Sun-Rype acquisition and of the gain realized in 2019 following the settlement of an insurance claim, the 2020 fourth-quarter profit attributable to the Company’s shareholders was up $6.8 million year over year.


Outlook

For the twelve-month period ended December 31, 2020, the Company noted a marked increase in industry sales volumes in the U.S. and Canadian fruit juice and drinks markets. Excluding Sun-Rype’s sales and foreign exchange impacts, the Company’s sales were up 6.8% in 2020 compared to 2019. It believes that a non-negligible portion of this increase could be due to the direct and indirect effects of the pandemic on consumer behaviour. In addition, the Company observed a change in its package mix relating to size of products purchased by consumers, as well as in the distribution channels used by them. There is no reliable way to determine whether these changes in purchasing habits are permanent or will fade when COVID-19 is a thing of the past. Barring any significant external shocks, including the impacts of the evolution of COVID-19 and the speed in which the restrictions will be lifted, the Company expects that, for 2021, it will be able to maintain a sales level similar to 2020. However, the uncertainty surrounding such a forecast is higher than it is under normal circumstances, as the impact in 2020 of the lockdown and physical distancing measures on demand for the Company’s products is hard to measure.

During 2020, the Company observed improved profitability at its U.S. operations due to strong demand for its products, although the competitive environment continues to be challenging at the private label level in the United States. However, it notes a rise of inflationary pressures, in particular on transportation costs affected by both scarcity of labour and equipment. In Canada, it expects to benefit from a full year of improvement in the production rate at one of its specialty food products plants, which was significantly affected by investment-related activities in 2019 and in the beginning of 2020.

The Company expects its investment-related cash outflows in 2021 to exceed the average of the last five years. Among other things, this increase is attributable to the upgrade of its ERP software in Canada. The Company also expects to make investments designed to increase its storage capacity at one of its Canadian plants and the production capacity for single-serve fruit juices and drinks in the United States. It believes that its use of investing cash flows could reach between $50 million and $60 million in 2021. These disbursements will have a limited impact on the Company’s profit for 2021 but will affect its cash flows.


About Lassonde

Lassonde Industries Inc. is a North American leader in the development, manufacture and sale of ready-to-drink juices and drinks marketed under brands such as Apple & Eve, Everfresh, Fairlee, Fruité, Graves, Oasis, Old Orchard, Rougemont and Sun-Rype. Lassonde is the largest producer of fruit juices and drinks in Canada and one of the two largest producers of store brand shelf-stable fruit juices and drinks in the United States. It is also a major producer of cranberry sauces. The Company also produces fruit-based snacks in the form of bars and bites.

Lassonde also develops, manufactures and markets specialty food products under brands such as Antico and Canton. The Company also imports and markets selected wines from various countries and manufactures apple ciders and cider–based beverages.

The Company produces superior quality products through the expertise of more than 2,700 people working in 17 plants across Canada and the United States. To learn more, visit www.lassonde.com.


Caution Concerning Forward-Looking Statements


 

In this document and in other documents filed with Canadian regulatory authorities or in other communications, the Company may from time to time make written or oral forward-looking statements within the meaning of applicable securities legislation. Forward-looking statements notably include estimates, expectations, forecasts, and projections of future investment spending, revenues, expenses, earnings, profit, indebtedness, financial position, losses, upcoming projects, business and management strategies, and business growth and expansion. In the context of this document, forward-looking statements are particularly used to discuss preliminary results, the rate of sales growth, and profit attributable to shareholders. The forward-looking statements contained herein are used to help readers better understand Lassonde’s financial position and the results of its operations as at the dates presented and may not be appropriate for other purposes. Forward-looking statements can be recognized by such words as “may,” “should,” “believes,” “predicts,” “plans,” “expects,” “intends,” “anticipates,” “estimates,” “projects,” “objective,” “continues,” “proposes,” “targets,” or “aims” as well as words and expressions of a similar nature and whether they are used in the affirmative or negative or used in the conditional or future tense. Forward-looking statements also include any statements that do not refer to historical facts.

By their very nature, forward-looking statements are based on assumptions and involve inherent risks and uncertainties, both general and specific in nature. It is therefore possible that the forecasts, projections and other statements will not be achieved or will differ significantly from those expressed or implied in such forward-looking statements or could affect the extent to which a particular forecast, projection or other statement materializes. Although Lassonde believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that these expectations will prove to be correct.

Readers are cautioned against placing undue reliance on forward-looking statements when making decisions, as the actual results could differ considerably from the opinions, plans, objectives, expectations, forecasts, estimates and intentions expressed in such forward-looking statements due to various significant factors. Such factors include, among others, the economic, industrial, competitive and regulatory environment in which Lassonde operates or factors that are likely to have an impact on its operations, its ability to attract and retain customers, consumers, and qualified staff, the availability and cost of raw materials and transportation, its operating costs, and the price of its finished products in the various markets where it operates.

The Company cautions that the foregoing list of factors is not exhaustive. For additional information about the risks, uncertainties, and assumptions that could cause Lassonde’s actual results to differ from its stated expectations, readers may also consult the “Uncertainties and Principal Risk Factors” section of the Company’s most recent annual MD&A and the other documents it files from time to time with securities regulators in Canada and available on sedar.com. The forward-looking statements contained in this press release reflect the Company’s expectations on this date and are subject to change after this date. Lassonde does not undertake to update publicly or to revise these forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable legislation or regulation.

SEDAR registration number: 00002099

SOURCE Lassonde Industries Inc.

MSCI Completes Private Offering of $500 Million 3.625% Senior Notes Due 2030

MSCI Completes Private Offering of $500 Million 3.625% Senior Notes Due 2030

NEW YORK–(BUSINESS WIRE)–
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today that it has successfully completed its private offering of $500.0 million aggregate amount of its 3.625% senior unsecured notes (the “Notes”) due 2030 (the “Offering”). The Notes constitute a further issuance of, are fully fungible with, rank equally with and form a single series with the $400.0 million aggregate principal amount of the 3.625% senior unsecured notes due 2030 issued on March 4, 2020. The Notes will mature on September 1, 2030.

MSCI intends to use the net proceeds from the Offering, together with available cash, for the pre-maturity redemption or repurchase of all $500.0 million aggregate principal amount outstanding of its 4.750% senior unsecured notes due 2026 (the “2026 Notes”) pursuant to the indenture governing the 2026 Notes (the “Redemption”).

MSCI expects to recognize additional expenses associated with this Redemption of the 2026 Notes and exclude such amounts from the calculation of adjusted earnings per share.

The Notes were offered only to (i) persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and (ii) certain non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act. The Notes have not been registered under the Securities Act or any state securities laws and therefore may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

About MSCI Inc.

MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to future events or to future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond MSCI’s control and that could materially affect actual results, levels of activity, performance or achievements.

Other factors that could materially affect actual results, levels of activity, performance or achievements can be found in MSCI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) on February 12, 2021 and in quarterly reports on Form 10-Q and current reports on Form 8-K filed or furnished with the SEC. If any of these risks or uncertainties materialize, or if MSCI’s underlying assumptions prove to be incorrect, actual results may vary significantly from what MSCI projected. Any forward-looking statement in this press release reflects MSCI’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MSCI’s operations, results of operations, growth strategy and liquidity. MSCI assumes no obligation to publicly update or revise these forward-looking statements for any reason, whether as a result of new information, future events, or otherwise, except as required by law.

MSCI Inc. Contacts

Investor Inquiries

[email protected]

Salli Schwartz +1 212 804 5306

Media Inquiries

[email protected]

Sam Wang +1 212 804 5244

Melanie Blanco +1 212 981 1049

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Finance Consulting Professional Services Other Technology Technology

MEDIA: